Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Editorial from The New England Journal of Medicine — CAR T-Cell Therapy for Large B-Cell Lymphoma — Who, When, and How?

  • This is such a great editorial that highlight several reasons why ZUMA 7 (using axi-cel) met its primary endpoint whereas BELINDA (using tisa-cel) did not meet its primary endpoint when compared to autologous transplant for patients with DLBCL in second line therapy.